BioSpace News Archive

Therapeutic Solutions International announced today receiving Investigational New Drug application number #28508 from the United States Food and Drug Administration for its proposed clinical trial evaluating the JadiCell™ in treatment of COPD.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has initiated the first in a series of studies to test the ability of its pancreatic cancer therapy to treat malignant ascites.

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering for the next generation of cell and gene therapies, has appointed Chad May, Ph.D., as the company’s Chief Scientific Officer.

Micro-Tech Endoscopy USA, the U.S. subsidiary of the global medical device company Micro-Tech (Nanjing) Co. Ltd, which develops and supplies diagnostic and therapeutic devices in the gastroenterology space, has announced a business partnership with Wision A.I., a startup in the field of artificial intelligence-assisted diagnostics for optical medical imaging.

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio at the 2022 American Society of Clinical Oncology Scientific Program (#ASCO22) and the European Hematology Association Congress (#EHA22).

Revance Therapeutics, Inc., a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference, taking place June 6-9, in Chicago.

Immunome, Inc. today announced updates to the ongoing development of its lead oncology program, IMM-ONC-01, a novel immuno-oncology agent that inhibits IL-38, an immunosuppressive cytokine.

Nanomix Corporation, a leader in the development of mobile, affordable, point-of-care diagnostics, is pleased to announce that it has upgraded to the OTCQB® Venture Market, and will continue to trade under the symbol NNMX.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced it has signed a second, exclusive research agreement with the Queensland University of Technology (QUT), Australia.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at 2:48 pm EST, with regard to the Company’s New Drug Application (“NDA”) for Fexapotide Triflutate.